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Introduction: Across the U.S., the prevalence of opioid use disorder (OUD) and the rates
of opioid overdoses have risen precipitously in recent years. Several effective medications
for OUD (MOUD) exist and have been shown to be life-saving. A large volume of research
has identified a confluence of factors that predict attrition and continued substance use
during substance use disorder treatment. However, much of this literature has examined
a small set of potential moderators or mediators of outcomes in MOUD treatment
and may lead to over-simplified accounts of treatment non-adherence. Digital health
methodologies offer great promise for capturing intensive, longitudinal ecologically-valid
data from individuals in MOUD treatment to extend our understanding of factors that
impact treatment engagement and outcomes.
Methods: This paper describes the protocol (including the study design and
methodological considerations) from a novel study supported by the National Drug
Abuse Treatment Clinical Trials Network at the National Institute on Drug Abuse (NIDA).
This study (D-TECT) primarily seeks to evaluate the feasibility of collecting ecological
momentary assessment (EMA), smartphone and smartwatch sensor data, and social
media data among patients in outpatient MOUD treatment. It secondarily seeks to
examine the utility of EMA, digital sensing, and social media data (separately and
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compared to one another) in predicting MOUD treatment retention, opioid use events,
and medication adherence [as captured in electronic health records (EHR) and EMA
data]. To our knowledge, this is the first project to include all three sources of digitally
derived data (EMA, digital sensing, and social media) in understanding the clinical
trajectories of patients in MOUD treatment. These multiple data streams will allow us to
understand the relative and combined utility of collecting digital data from these diverse
data sources. The inclusion of EHR data allows us to focus on the utility of digital health
data in predicting objectively measured clinical outcomes.
Discussion: Results may be useful in elucidating novel relations between digital data
sources and OUD treatment outcomes. It may also inform approaches to enhancing
outcomes measurement in clinical trials by allowing for the assessment of dynamic
interactions between individuals’ daily lives and their MOUD treatment response.
Clinical Trial Registration: Identifier: NCT04535583.
Keywords: opioid use disorder (OUD), digital phenotyping, medication for opioid use disorder (MOUD), ecological
momentary assessment (EMA), passive sensing, social media

INTRODUCTION

on an episodic basis and may not reflect factors in individuals’
daily lives that impact their OUD treatment trajectories. Thus,
there is tremendous opportunity to more frequently and
extensively examine factors that impact individuals’ clinical
trajectories in MOUD in real time.
Digital methodologies offer great promise for capturing
intensive, longitudinal ecologically-valid data from individuals
receiving MOUD to extend our understanding of factors
that impact treatment engagement and outcomes (29, 30).
In particular, the use of digital devices such as smartphones
or wearables that measure individuals’ health-related behavior
(sometimes referred to as “digital phenotyping”) (31) has the
potential to provide personalized health care resources. The
ubiquity of digital devices and the explosion of “big data”
analytics enable the collection and interpretation of enormous
amounts of rich data about everyday behavior. This includes
the use of digital devices to implement “ecological momentary
assessment” (EMA) (32) in which individuals are asked to
respond to brief queries on their mobile devices (assessing,
for example, craving, mood, withdrawal symptoms, and pain).
It also includes passive sensing data collected via sensors
embedded in smartphones and/or wearable sensing devices such
as smartwatches that provide information about the wearer’s
health (e.g., heart rate and heart-rate variability measured via
wearable photoplethysmography), behavior (e.g., social contact
via calls, texts and app use), and environment (e.g., location type
via GPS) (33). And, it includes social media data that individuals
produce (e.g., the images and the texts they post).
A rapidly growing literature is underscoring the utility of such
digital health data-driven approaches to understanding human
behavior (34–37). Digitally-derived data may similarly reveal
new insights into the temporal dynamics between moderators
and mediators of MOUD treatment outcomes. Such data may
complement and extend data captured via structured clinical
assessments and provide a more comprehensive understanding
of each individual’s course of treatment. And these data, in turn,

Across the U.S., the prevalence of opioid use disorder (OUD) and
the rates of opioid overdoses have risen precipitously in recent
years. Drug overdose has been called a “modern plague” (1) and
is the leading cause of death of Americans under age 50, having
surpassed peak death rates from gun violence, HIV, and car
crashes (1, 2). Over 100,000 Americans died from a drug overdose
from May 2020 to April 2021 (3). This dramatic spike in OUD has
also been accompanied by marked increases in injection-related
infections (including infective endocarditis and Hepatitis C) (4–
7), babies born with Neonatal Opioid Withdrawal Syndrome (8)
and healthcare and criminal justice costs (9).
Several effective medications for OUD (MOUD) have been
shown to be life-saving including buprenorphine, methadone,
and naltrexone products (10, 11), and to greatly increase
opioid abstinence, reduce HIV/infectious disease risk behavior,
and reduce criminality. Greater MOUD retention is associated
with the most positive treatment outcomes (12–16). However,
over 50% of patients receiving MOUD dropout of treatment
within 3–6 months after treatment initiation (17–21), falling
short of the longer threshold of treatment shown to offer
sustained benefit (22, 23). Additionally, given the chronic
relapsing nature of the disease of addiction, and inconsistent
compliance with MOUD, many individuals continue to engage
in opioid use during treatment, increasing the risk of overdose
(24, 25).
Many factors predict attrition and continued substance
use during substance use disorder (SUD) treatment (26,
27), including, stress, mental health comorbidities, continued
exposure to high-risk social networks or contexts, and the
neurobiology underpinning addiction. However, this literature
has examined a limited set of predictors of outcomes in MOUD
treatment and may not reflect a comprehensive understanding of
treatment non-adherence (28). Further, treatment engagement is
typically evaluated via structured clinical assessments conducted

Frontiers in Psychiatry | www.frontiersin.org

2

April 2022 | Volume 13 | Article 871916

Marsch et al.

Digital Health Feasibility and Utility

may increase our ability to develop more potent and personalized
treatment models for OUD.
The developing literature on the application of digital health
to understanding individuals’ trajectories in SUD treatment
has shown promise. One study that used EMA to identify
predictors of substance use among adults after an initial episode
of SUD treatment showed high EMA completion rates (81%)
and identified specific substance use patterns, negative affect and
craving as predictors of substance use (38). EMA research has
also demonstrated differing relationships between drug triggers
(e.g., exposure to drug cues or mood changes) and different types
of drug use. Specifically, drug triggers increased for hours before
cocaine use events but not before heroin use events (39). And,
among smokers trying to quit, smoking lapses were associated
with increases in negative mood for many days (and not just
hours) (40).
Additionally, EMA research with adults in MOUD treatment
demonstrated a stronger relationship between craving and drug
use events than between stress and drug use events (41). EMAassessed momentary pain has been shown to be indirectly
associated with illicit opioid use via momentary opioid craving
(42). Further, MOUD treatment dropout has been shown to
be more likely among individuals who report more “hassles”,
higher levels of cocaine craving, lower levels of positive mood,
a recent history of emotional abuse, and a recent history of being
bothered frequently by psychological problems. It is noteworthy
that none of those factors predicted individuals’ non-compliance
with completing EMA (43). Other EMA research revealed that
patients in MOUD treatment who share similar patterns of drug
use (frequent opioid use, frequent cocaine use, frequent dual use
of opioids and cocaine, sporadic drug use, or infrequent drug use)
tended to have similar psychological processes preceding drug
use events (44).
Less research has focused on the utility of passively collected
sensing data or social media data in predicting substance use.
One study used GPS data from phones to assess exposure to
visible signs of environmental disorder and poverty among adults
in outpatient MOUD treatment. That study provided a proof of
concept that digitally-captured environmental data could predict
drug craving and stress 90 min into the future (45). Another
study with adults in outpatient MOUD, focused on passive
assessment of stress, showed that the duration of a prior stress
episode predicts the duration of the next stress episode and that
stress in the mornings and evenings is lower than during the
day (46). And another study demonstrated that deep-learning
analytic approaches applied to social media data may be useful in
identifying potential substance use risk behavior, such as alcohol
use (47).
Overall, these findings have provided some new insights
into how data collected in naturalistic settings may enhance
an understanding of risk profiles among individuals in SUD
treatment. Nonetheless, the breadth of factors evaluated to date
has been limited, and most digital health studies conducted
with populations in SUD treatment have relied exclusively on
self-reported clinical outcomes (with limited focus on objective
metrics such as urine screens, medication fills, and clinical visits).

Frontiers in Psychiatry | www.frontiersin.org

Additionally, most studies have solely sought to predict substance
use events.
This paper describes the protocol (including the study
design and methodological considerations) from a novel study
supported by the National Drug Abuse Treatment Clinical
Trials Network (CTN) at the National Institute on Drug Abuse
(NIDA). This study, referred to as “Harnessing Digital Health
to Understand Clinical Trajectories of Opioid Use Disorder” (DTECT; CTN-0084-A2) primarily seeks to evaluate the feasibility
of collecting EMA, digital sensing and social media data among
patients in outpatient MOUD treatment. It secondarily seeks to
examine the utility of EMA, digital sensing, and social media
data (separately and compared to one another) in predicting
MOUD treatment retention, opioid use events, and medication
adherence [as captured in Electronic Health Records (EHR),
medical claims, and EMA data]. This is the first project to include
all three sources of digitally derived data (EMA, sensing and
social media) in understanding the clinical trajectories of patients
in MOUD treatment. Multiple data streams will allow us to
understand the relative and combined utility of collecting digital
data from these diverse data sources. The inclusion of EHR data
allows us to focus on the utility of digital health data in predicting
objectively measured clinical outcomes.

METHODS AND ANALYSIS
Overview of Study Design
Individuals with OUD will be recruited for the study from
among patients who are active in outpatient MOUD treatment
with buprenorphine medication for at least 2 weeks at one of
four Addiction Medicine Recovery Services (AMRS) programs
at Kaiser Permanente Northern California (KPNC). Once it is
confirmed that eligibility criteria are met, each participant will
provide electronic informed consent and complete the baseline
assessment by phone. The baseline appointments will take ∼2.0 h
to complete, which will be done in two to three visits. Participants
will be asked to wear a smartwatch and carry a smartphone (a
study-supplied one or their own) that will passively collect sensor
data. They will be asked to actively respond to EMA prompts
through a smartphone 3 times daily and to self-initiate EMA
responses daily if substance use occurred over the 12-week study.
For those who consent to the optional social media component,
social media data will be downloaded by the participant directly
from the social media platform to a secure server using a remote
desktop at the beginning of the study and again at the end of the
study. EHR data extraction will occur at ∼16 weeks after the full
study is completed and will collect data 12 months prior to EMA
start (the date the participant began receiving EMA prompts)
through 12-weeks after EMA start (84 days after the EMA start
date). A follow-up assessment (∼45 min in length) will occur by
phone ∼12 weeks after EMA start. A graphic overview of the
study phases is presented in Figure 1.

Study Sites and Rationale for Site Selection
KPNC is a large, integrated health care delivery system with
4.3 million members, providing care through commercial
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FIGURE 1 | Study phases.

for 12 weeks; and willing to wear a smartwatch continuously
(except during pre-defined activities such as showering) for 12
weeks. Individuals will be excluded if they are: unwilling or
unable to provide informed consent; currently in jail, prison
or other overnight facility as required by court of law or have
pending legal action that could prevent participation in study
activities. We expect to recruit 50–75 participants.

plans, Medicare, Medicaid, and health insurance exchanges.
It is comprised of a racially and socioeconomically diverse
membership and is generally representative of the region’s
population with access to care. KPNC was selected based on its
ability to (1) provide access to individuals who are prescribed
buprenorphine for OUD and (2) provide access to EHR data
on treatment retention, medication adherence, and service
utilization. KPNC maintains a data repository, the Virtual Data
Warehouse, which has combined EHR data (e.g., demographics,
membership, diagnoses, service utilization, pharmacy, lab data)
with several other data sources, including medical claims data
(e.g., non-Kaiser pharmacy data).
The AMRS programs at KPNC offer a broad range of services,
including prescribing buprenorphine for OUD, medical services,
group and individual therapy, and family therapy. Staffing
includes physicians, therapists, medical assistants, nurses, and
social workers.

Study Procedures
Recruitment and Screening
Potentially eligible patients will be initially identified from EHR
data as meeting study criteria; eligibility is further confirmed
through chart review. Eligible patients will be sent an invitational
recruitment letter through a secure email message. Within
approximately a week of mailing recruitment letters (or sending a
secure email message), research staff will contact participants by
phone to determine if they are interested and eligible, using the
IRB-approved recruitment script, verbal consent form and final
screening questions. If the individual is interested and eligible,
research staff will schedule them for an initial baseline phone
appointment and email them consent documents for their review
before their appointment.

Participants
Participants will include individuals aged 18 years or older across
all racial and ethnic categories. Eligibility criteria include: active
in KPNC outpatient treatment and prescribed buprenorphine for
OUD for the past 2 weeks (and attended at least one visit at
AMRS in past 35 days); >18 years old; capable of understanding
and speaking English; able to participate in the full duration of
the study (12 weeks); have an active email account and willing
to provide its address to researchers; permit access to EHR data;
willing to carry and use a personal or study-provided smartphone

Frontiers in Psychiatry | www.frontiersin.org

Informed Consent
Informed consent will be obtained by phone and documented
online using an electronic signature. Each participant will be
asked to pass a brief consent quiz to document comprehension
of the study activities. The research staff will obtain authorization
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Engagement in Research

from participants for use of protected health information, such as
their EHR and medical claims data.

To be considered engaged in the study, an individual must
respond to a minimum number of EMA prompts (complete at
least 2/3 of the EMA surveys per day on 7 out of the first 14
days) and record at least 8 h of smartphone/smartwatch sensor
data per day on 7 out of the first 14 days of study participation. If
an individual does not meet the engagement criterion and is nonresponsive to research staff outreach in the first 14 days of study
participation, then the individual will be considered a “nonengager” and the study team will continue to recruit until the
targeted sample size is met. Non-engagers will not be withdrawn
from the study, as we will attempt to collect all possible data from
all participants.

Baseline
The baseline process will be conducted in two or three phone
appointments: the first appointment will consist of informed
consent and the baseline assessment (Baseline 1), and the second
(and third, if necessary) appointment (Baseline 2/3) will consist
of a urine drug screen, setting up study devices, installing study
applications (“apps”), and learning to use devices and apps
(Figure 1).
The baseline assessment consists of intervieweradministered measures (described below) examining participant
characteristics, current substance use (e.g., tobacco, alcohol,
opioids, and other drugs), substance use and mental health
disorders, and the impact of the COVID-19 pandemic. Once
the first baseline appointment is completed, participants
will be mailed a urine drug screen kit, a smartwatch
and study smartphone (if applicable) and technology
training documentation.
Once the equipment is received, research staff will schedule
a second phone appointment with each participant to review
the urine collection and technology training documentation.
Research staff will walk through the set-up, use and care of the
smartphone and smartwatch, installation of the study app and the
Garmin Connect app (described below) if they are not already
installed on a study-provided phone, as well as instructions
for initiating and completing the daily EMA surveys. Research
staff will also instruct participants to collect a urine sample and
upload results.
Participants who consented to the social media part of the
study will also receive instruction on how to request and
download their social media data.

Follow-Up
A follow-up assessment will be completed by phone ∼12 weeks
post-EMA start. Research staff will administer an interviewerbased assessment to measure current substance use, participant
experience with the study devices, treatment utilization, reasons
for drop out (if appropriate), employment, insurance coverage,
medication use/dose (if applicable), and overdose (if applicable).
Participants will be mailed a urine drug test kit and asked to
collect another urine sample and upload test results. Participants
who consented to the social media part of the study will
be asked to request and download their social media data a
second time.

Description of Measures
A summary of the clinical assessments and digital health
assessments to be conducted in this study are reflected in
Figures 2, 3, respectively. Brief descriptions of each of these
measures is provided below.
Prisoner Status Assessment: An individual’s prisoner
status must be assessed for each participant at each separate
encounter, as this study will not apply for Office of Human
Research Protection (OHRP) Prisoner Certification. An
Inclusion/Exclusion form will be used to obtain information on
inclusion and exclusion criteria to document eligibility. Locator
Form. A locator form is used to obtain information at baseline
and each contact to assist in finding participants throughout the
study. This form collects the participant’s current address, email
address, and phone numbers. PhenX Substance Abuse and
Addiction Core Tier 1 (PhenX Core Tier 1). The PhenX Core
Tier 1 is a part of the Substance Abuse and Addiction Collections
(48) that are being adopted across multiple studies funded by
NIDA. This study will use the following subset of measures
from the Core Tier 1: demographics (age, ethnicity, gender,
race, current educational attainment, current employment
status, and current marital status) and current substance use
(tobacco, alcohol, and drugs) (49). The demographics (except
for employment status) will only be collected at baseline, while
current substance use and current employment status will be
collected at baseline and follow-up. The PhenX Substance Abuse
and Addiction Core Tier 2 (PhenX Core Tier 2). The PhenX
Core Tier 2 is a complementary set of 8 measures to the PhenX
Core Tier 1 (i.e., annual family income, child-reported parental
education attainment, family history of substance use problems,

Active Study Phase (12-Weeks)
During the active 12-week study phase, the research staff will
monitor participant compliance using a custom dashboard
(e.g., their EMA completion rate and whether they carry the
study phone and wear the study watch). In the first 2 weeks,
participants will be followed closely. If after a 48-h period there
are no EMA data, and/or no phone carry time data, and/or
no watch wear data, research staff will follow-up directly with
the participant via phone, text, and/or email to encourage the
participant to continue their participation and/or troubleshoot
any problems that may arise with the smartphone, smartwatch,
and/or study app. All participants will have a 1-week checkin appointment via phone with research staff to review the
participant’s experience, review data collection over the past
week, and answer any questions or resolve any technical issues
with the study devices (regardless of device carry/wear time
compliance or EMA completion rate). Thereafter, research staff
will send weekly check-in texts or phone calls unless there is a
48-h period of no EMA data, and/or no phone carry time data,
and/or no watch data. In those instances, the research staff will
attempt to reach the participant by phone, text, and/or email.
The research staff will make up to three contact attempts prior
to engaging alternate contact(s).

Frontiers in Psychiatry | www.frontiersin.org
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FIGURE 2 | Table of study assessments. *NSDUH is only collected for participants who are unsure of the total family income. We will use as subset of questions to
determine which income category best characterizes total combined family income. **EHR/Medical Claims data will be extracted by the data analyst ∼16 weeks after
completion of study and includes data 12 months prior to EMA start through 12 weeks post-EMA start.

household roster-relationships, internalizing, externalizing,
and substance use disorders screener, occupation/occupational
history, peer/partner substance use and tolerance of substance
use, and social networks) (50). This study will only use a subset
of questions from the Annual Family Income measure to get
an estimate of total income of all family members (49). If the
participant is unsure of the total family income, then we will
use a subset of questions from the Substance Abuse and Mental
Health Services Administration’s National Survey on Drug
Use and Health (NSDUH) survey to determine which income

Frontiers in Psychiatry | www.frontiersin.org

category best characterizes total combined family income (51).
These measures will be securely, electronically stored in a
REDCap database.
NetSCID-5: The Structured Clinical Interview for DSM5 (SCID-5) is a semi-structured interview designed to assess
substance use and mental health diagnoses (52). This study
will use an electronic version of the SCID-5, the NetSCID5, developed by TeleSage. The TeleSage NetSCID-5 is fully
licensed by the American Psychiatric Association and has
been validated (53). TeleSage has the capability of customizing
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FIGURE 3 | Active study phase digital health assessments. *Wear smartwatch at least 18 hours per day, data transmitted real-time for 12 weeks. **Carry smartphone
at least 8 hours per day, data transmitted real-time for 12 weeks. ***3 times per day for 12 weeks.

real-time (while the participant is still on the phone). Research
staff will review the photos that are sent to ensure that the
results captured within the photos are legible and not blurry or
otherwise indecipherable.

the NetSCID-5 measure, and modules relevant for this study
include: bipolar I disorder, major depressive disorder, panic
disorder, social anxiety disorder, generalized anxiety disorder,
posttraumatic stress disorder, adult attention deficit hyperactivity
disorder, alcohol use disorder, and other use disorders [cannabis,
stimulants/cocaine, opioids, phenylcyclohexyl piperidine (PCP),
other hallucinogens, inhalants, sedative-hypnotic-anxiolytic, and
other/unknown]. The TeleSage NetSCID-5 will be administered
by research staff who are trained and credentialed to conduct this
diagnostic assessment.
Urine Drug Screen: Urine drug screen kits will be mailed
to participants, and participants will be asked to collect a
urine sample and then record and upload its results using a
secure system (e.g., REDCap) at first baseline appointment and
at follow-up. All urine specimens are collected using CLIAWaived and FDA-approved one-step multi-drug screen test
cups following the manufacturer’s recommended procedures.
The study will use the DrugConfirm Advance Urine Drug
Test Kit that screens for: alcohol, amphetamine, barbiturate,
buprenorphine, benzodiazepine, cocaine, fentanyl, MDMA
(ecstasy/molly), methamphetamine, methadone, morphine
300 ng/mL, oxycodone, phencyclidine (PCP), tramadol and
delta-9-tetrahydrocannabinol (THC).
In order to reduce risks of substituted or adulterated urine
samples, the research staff will conduct the study urine drug
screens in real-time (i.e., reviewing collection instructions and
walking the participant through the entire process via phone)
during the Baseline 2 phone appointment. Participants will send
a photo of the temperature strip to research staff immediately
after they produce the sample to ensure the temperature is within
the specified valid temperature range of 90◦ -100◦ F. Additionally,
we will ask participants take photos of the test result strips
and send the photos of the results securely to research staff in

Frontiers in Psychiatry | www.frontiersin.org

Digital Health Technology
Ambulatory Physiological Assessment Using Mobile
Sensors
We will develop a smartphone application (“study app”) for
both Android and iOS devices. The study app can sense and
store contextual information about a participant, e.g., location,
physical activity (step count), conversation duration and count
(non-identified audio information such as segments of silence,
and speech features such as pitch control and voice quality),
app usage, call/text, screen on/off, phone lock/unlock, and phone
notifications (54). Features will be derived from the raw sensor
streams to create multiple relevant contextual variables. This
custom application will be installed directly on the studyprovided smartphone (Moto G7 Power and/or Moto G Power)
or on a participant’s smartphone if they have a compatible phone
(iPhones, running iOS 12 or higher or Android devices running
Android 8.0 or higher with at least 2.5 GB RAM and 4 GB of
available storage).
In addition to the smartphone, participants will be provided
with a smartwatch (Garmin Vivosmart 4). The participants will
be asked to wear the smartwatch continuously (except during
pre-determined exception periods, such as when the participants
are showering or charging the device). The Garmin Vivosmart
4 smartwatch is comfortable, lightweight, and has a long battery
life of up to 7 days (55) and an easy-to-use interface. The device
can continuously collect and track a variety of sensor data in the
background, as long as the user is wearing the device. The data
from the wearable is synced directly with Garmin cloud servers,
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of the study is optional; participants can still participate in the
study and decline to provide their social media data.
We will parse the JSON/JS files of the downloaded social
media data to extract the information of interest, including
posting date, text, and corresponding image paths on a local
storage. We will aggregate the extracted data into a pickle file
composed of different data dictionaries for text, posting dates,
and local image paths. It is noteworthy that all the social media
data from three variant platforms will be in the same format
after processing. We plan to collapse and aggregate the data
collected across the three social media platforms to reduce data
sparsity and thereby increase the number of study days that are
represented in the training and evaluation data sets.

using the “Garmin Connect” application installed on the phone,
and we will not have direct access to the raw sensor data. We
will use the Garmin Health Connect API to get various health
metrics that are computed by Garmin’s proprietary algorithm,
such as heart rate, sleep stage information (i.e., periods and
events of light/deep sleep), stress levels, and physical activity
levels (including energy expenditure) and step counts). Through
the Garmin Health Connect API, Garmin’s servers will push
the various metrics computed from the raw data to the storage
servers at Dartmouth College.

Ecological Momentary Assessment
Participants will be prompted 3 times per day over 12 weeks
by the smartphone app to self-report sleep, stress, pain severity,
pain interference, pain catastrophizing, craving, withdrawal,
substance use risk context, mood, context, substance use, selfregulation, and MOUD adherence (41, 56–59). The EMA prompt
delivery times will be randomized within each of the prompt
timeframes (e.g., morning, mid-day, end of day). In addition to
prompted EMAs, participants will be asked to self-initiate EMA
responses if substance use occurred (e.g., opioids, cocaine, or
other stimulants). When determining the rate of completion of
self-initiated reports of substance use, we will be able to crossreference responses to the following question asked in the “End
of the Day” EMA prompt (“Did you use any drugs at all today
without reporting it?”) with participant’s self-initiated substance
use EMA data.
Additionally, participants will be asked to complete a
Momentary Self-Regulation Scale1 via EMA. This brief 12item questionnaire assesses self-regulation on a momentary basis
as individuals move through their daily lives. This information
will be collected 3 times daily over the 12-week study period
by smartphone.

EHR Data
EHR data extraction will include all outpatient and inpatient
encounters, medications, procedures, and diagnoses for the 12
months prior to EMA start and the 12-week study period.
In addition, we will extract lab results from urine drug
screens, patient demographic information, KPNC health plan
membership status, and insurance deductible level. We will
extract appointment data to determine if visits were canceled
or missed. KPNC is also an insurance plan and has claims data
on non-KPNC services that were submitted as medical claims
for reimbursement.

Clinical and Safety Assessments
Clinical and safety events may be elicited at baseline or
spontaneously reported to study staff at any encounter
following consent. Safety events suggesting medical or psychiatric
deterioration will be brought to the attention of the study
clinician for further evaluation and management.

Compensation
Participants will be compensated up to $21 per week for
completing EMA surveys, up to an additional $10 per week bonus
for completing a minimum of 80% of received EMAs, and up
to $14 per week for carrying their smartphone at least 8 h per
day and wearing the smartwatch at least 18 h per day. At the
end of the 12-week active phase of the study, participants will
receive a $50 bonus for either using their personal smartphone
or returning a study-provided smartphone, and a $50 bonus for
returning the study-provided smartwatch. Finally, participants
who consent to the social media portion of the project will receive
up to an additional $180. Total possible compensation will be up
to $820 over the course of the 12-week active study phase for
the digital data collected (i.e., each EMA completed plus EMA
bonus, smartphone carry time met and smartwatch wear time
met, and social media data download, if applicable). In addition
to the earnings and bonuses (described above), an individual who
completes a minimum of 80% of received EMA surveys within
a given week will qualify for a drawing at the end of that week
where the individual could win a $50 prize. Each individual will
have an opportunity to participate in up to 12 drawings over the
12 weeks. During the 12-week active study phase, any incentives,
bonuses, and/or drawings earned will be uploaded weekly to a
reloadable debit card. Study participants will be compensated

Social Media
Participants will be asked to request and then download their
social media data (Facebook, Instagram, or Twitter) to a secure
server using a remote desktop application. These three social
media platforms provide the functionality for each user through
their account setting to download their social media data as
an aggregated structured file. After requesting a data download
from a social media website, the participant will receive an
email notification when the downloadable copy of the data has
been created—typically in <48 h from the request. Once the
social media data are ready to download, the participant will log
into a remote computer located at Dartmouth College by using
Microsoft Remote Desktop and will download their social media
data to the secure research study computer. After completing the
download, the participant will sign out of the remote computer
and alert the research team. Images and text postings as well as
date/time for each post will be extracted from the downloaded
social media data. As noted elsewhere, participation in this part
1 Scherer EA, Kim SJ, Metcalf SA, Sweeney MA, Wu J, Xie H, et al. The development

and validation of a momentary self-regulation scale. JMIR Mental Health
(under review).
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nested data structures by incorporating both fixed effects and
random effects, which would allow us to examine both inter
and intra-individual differences. Machine learning models can
also be integrated with the random-effects structure as in the
mixed-effect models (61). In the cross-validation, the training
data will be split into k-folds by patient id. Previous work
has shown that whether training data is split by record or by
patient can significantly affect model performance (62), with
better performance typically being achieved when splitting data
by record rather than by participant.
For social media data, we will use deep neural networks for
feature extraction and predictive analysis. Specifically, pretrained
residual neural network (ResNet) (63) will be used to extract
features from images and bidirectional encoder representations
from transformers (BERT) (64) models will be used to extract
features from text. Using these neural networks, social media
images and text can be represented as dense vectors that can
be aggregated with the rest of the collected data for predictive
analysis. We will also explore classic machine-learning methods
(such as random forest, support vector machines, and gradient
boosted trees) for social media-based prediction, and compare
their results to the performance of deep neural networks.
Typical evaluation methods used to assess the prediction quality
include area under the receiver operating characteristic curve
(AUROC), accuracy, precision, F-score, sensitivity (recall), and
specificity. The relative utility of the various data for predicting
outcomes will be assessed at two levels - individual features
and aggregated features (e.g., Facebook, Twitter, GPS, step,
sleep, mood). The contribution of each feature in predicting
the outcome variable will be assessed using a model-agnostic
machine-learning approach to reverse-engineering algorithms by
perturbing model inputs based on game theory, SHapley Additive
exPlanations (SHAP) (65, 66).
When missing data are encountered, we will apply domain
knowledge to reflect on the probable reasons that the data are
missing. Based on our knowledge-based assessment of the nature
of the missing data, missing samples will be imputed using
appropriate imputation methods (67, 68).
There are at least two approaches to integrating data from
the three data sources for use by a single prediction model,
depending on whether the prediction models operate in a lowerdimensional “latent/embedding space” or a higher-dimensional
“feature space”. Deep learning models typically operate in the
latent/embedding space, while other machine learning models
(e.g., Random Forest, Gradient Boosted Regression Tree) operate
in the feature space.
When combining data in the feature space, features must
be engineered from both structured and unstructured data.
The unstructured social media data, in particular, may require
manual or automated annotation in order to generate features.
When combining data in the latent space, models that convert
both structured and unstructured data into the latent space
will be required. These models could be pre-trained on other
similar data sources (e.g., BERT for natural language text, pretrained ResNet model on ImageNet for image data, Activity2Vec
for sensor data). We are not aware of pre-trained models for
generating embeddings from EMA/survey data.

$75 for completing the baseline appointments and baseline urine
drug screen (via Target gift card), and $100 for completing the
12-week follow-up appointment and follow up urine drug screen
(via Target gift card). Total compensation will be up to $995 for
participating in all study activities [digital compensation ($820)
plus baseline and follow-up appointment compensation ($175)].

Statistical Analyses
Primary and Secondary Outcomes (Endpoints) and
Hypotheses
The primary outcomes will include (1) the percentage of days
during the 12-week active phase enrolled participants met criteria
for wearing the smartwatch and carrying the smartphone; (2)
the response rate to EMA prompts during the 12-week active
phase; and (3) the percentage of participants who consent to
social media data download and sparsity of social media data
per participant. We hypothesize that the majority of participants
who enroll in the study will wear the smartwatch, carry the
smartphone, respond to EMA prompts, and be willing to share
their social media data with the research team. We expect the
number of participants deemed “non-engagers” will be low.
The secondary outcome measures will be (1) OUD treatment
retention (days retained in OUD treatment program) based on
EHR data; (2) days covered on MOUD based on EHR and EMA
data; and (3) non-prescribed opioid use based on EHR and
EMA data. We hypothesize that intensive longitudinal digital
data capturing patient context and psychological state will be
useful for predicting treatment retention, opioid use events and
buprenorphine medication adherence.

Statistical Methods
For our primary feasibility assessment for primary and secondary
outcomes, we will generate descriptive statistical summaries
of the level of adherence of study participants to the desired
protocol (e.g., EMA response rate, smartwatch wear rate and
smartphone carry rate).
For our predictive analyses for primary and secondary
outcomes, we are interested in measuring and predicting
outcomes that may occur repeatedly over a 12-week
observational period (e.g., patterns of daily drug use) using
digital health technology. In digital health the spatio-temporal
granularity of information about an individual is of higher
resolution than that obtained through cross-sectional or
traditional longitudinal studies (60). We will therefore assess
the utility of using data from smartphones, smartwatches, social
media, and ecological momentary assessment to predict, explain
and detect these outcomes.
Our approach to prediction will include regression methods
(e.g., logistic regression), but we will also use various machinelearning approaches for binary classification (e.g., random forest,
support vector machines, K-means, gradient boosted trees,
neural networks). For each of these classification techniques, we
will assess the utility of the various digital data for improving
prediction quality.
The study will generate the nested longitudinal data with
binary response sequences collected over time. The regression
model (logistic regression) will be built to account for the
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Yet another approach for “integrating” all 3 data sources is
to train separate models using each dataset and an ensemble
predictor that combines the predictions from each model to
generate a final prediction, e.g., bagging or accuracy-weighted
ensemble (69).
We will perform k-fold cross validation (CV) when evaluating
the performance of the prediction models. We will do a group kfold CV where instead of randomly splitting all data into k-folds,
we will divide our dataset into k groups such that each participant
is assigned to only one group with no overlap between the groups.
This is to prevent any data leakage that might happen due to a
participant’s data being present in the train and test sets.
This is an exploratory pilot study. Therefore, a detailed
analysis of statistical power to detect effects was not performed.
As we are predicting daily outcomes (e.g., daily medication
adherence, daily drug use), the sample size that is potentially
available to us is equal to the number of participants multiplied by
the number of study days. For example, assuming 60 participants
in the study, and a study period of 12 weeks (i.e., 84 days), the
analytic sample size would be 60∗ 84 = 5,040 participant-days.
If the observed incidence of non-adherence or drug use is 10%,
then we would observe ∼504 non-adherence or drug use events.
Results of this study may generate a data set that could be helpful
for future researchers to estimate the likely power of predictive
models for this patient population, using similar sources of data.

The studies involving human participants were reviewed and
approved by the Institutional Review Board (IRB) at Kaiser
Permanente Northern California (the single IRB overseeing
this study). The patients/participants provided their written
informed consent to participate in this study. We plan to
disseminate findings from this research at scientific meetings
and in multiple peer-reviewed publications, including results of
analyses assessing the feasibility of using EMA, digital sensing
and social media data among adults in outpatient MOUD and
analyses assessing the predictive utility of these data sources in
predicting MOUD treatment retention, opioid use events, and
medication adherence.

AUTHOR CONTRIBUTIONS
LM, CC, C-HC, SH, DK, CL-H, and CS were responsible for
developing the study design for this project. LM wrote the initial
draft of the protocol paper. AA, CC, MD, MJ-M, HJ, CL-H, and
BM were involved in study coordination and operations. GS was
the study’s Scientific Officer. SA, CL-H, VM, and WW prepared
the data sets for analyses. NJ consulted on the statistical analysis
plan. C-HC, ZL, VM, and WW conducted the statistical analyses.
EH prepared the references. All authors participated in the review
and revision process and approved the submission of this version
of the protocol paper.

DISCUSSION
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In a world that is rapidly embracing digital health approaches
to understand and provide resources to support health behavior,
this study is distinct in that it will be the first to systematically
assess the feasibility and utility of digitally-derived data from
EMA, passive sensing and social media, all collected from
the same sample of individuals in MOUD treatment. Results
from this study may be useful in elucidating novel relations
between digital data sources and treatment outcome. It may
also inform approaches to enhancing outcomes measurement
in clinical trials by allowing for the assessment of dynamic
interactions between individuals’ daily lives and their MOUD
treatment response. It may additionally inform specific digital
data collection protocols in the next phase of this line of research,
including the need to abbreviate EMA questions to capture those
most clinically useful and/or strategies for addressing any privacy
or data sharing concerns that may arise among participants.
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